Caraco settles with US FDA on GMP violations
This article was originally published in Scrip
Executive Summary
Caraco Pharmaceutical Laboratories has entered into a consent agreement with the US FDA that bars the company from re-starting generic drug manufacturing operations at its facilities in the Detroit, Michigan, area until they comply with good manufacturing practices (GMPs).